Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth

Journal of Hypertension

Volumn 22, Issue 1, 2004, Pages 121-127

  Kamide, Kei ^a,b   Rakugi, Hiromi ^a   Nagai, Michiko ^a   Takiuchi, Shin ^a,b   Matsukawa, Naomichi ^a   Higaki, Jitsuo ^c   Kawano, Yuhei ^b   Ogihara, Toshio ^a   Tuck, Michael L ^d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin coverting enzyme; Angiotensinogen; Insulin; Renin; Vascular endothelial cells

Indexed keywords

ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; INSULIN; MESSENGER RNA; RENIN; THYMIDINE;

ANALYTIC METHOD; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SLOT BLOT HYBRIDIZATION; VASCULAR ENDOTHELIUM;

EID: 1442299097     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200401000-00021     Document Type: Article

References (21)

1. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 344:374-381.
2. Kamide K, Nagano M, Nakano N, Yo Y, Kobayashi R, Rakugi H, et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996; 9:1165-1171.
3. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957.
4. Kamide K, Rakugi H, Nakano N, Ohishi M, Nakata Y, Takemi S, et al. Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. Am J Hypertens 1997; 10:1245-1249.
5. Kamide K, Hori M, Zhu JH, Barrett JD, Eggena P, Tuck ML. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998; 32:482-487.
6. Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical application. Am J Cardiol 2002; 90:40L-48L.
7. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66:529-533.
8. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol 2002; 21:109-116.
9. Iiyama K, Nagano M, Yo Y, Nagano N, Kamide K, Higaki J, et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996; 132:779-782.
10. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathway in the metabolic syndrome. Curr Hypertens Rep 2002; 4:105-111.
11. Rakugi H, Ogihara T. Role of angiotensin in the metabolic syndrome and cardiovascular complications. Nippon Rinsho (Japanese) 2002; 60:1898-1903.
12. Fishel RS, Thourani V, Eisenberg SJ, Shai SY, Corson MA, Nabel EG, et al. Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. J Clin Invest 1995; 95:377-387.
13. Cheung HS, Cushman DW. Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops Jararaca. Biochim Biophys Acta 1973; 293:451-463.
14. Kamide K, Hori M, Zhu JH, Takagawa Y, Barrett JD, Eggena P, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18:1051-1056.
15. Steil GM, Ander M, Moore DM, Rebrin K, Bergman RN. Transendothelial insulin transport is not saturable in vivo: no evidence for a receptor-mediated process. J Clin Invest 1996; 97:1497-1503.
16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
17. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
18. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 1997; 100:2158-2169.
19. Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8:353-357.
20. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101:676-681.
21. Nagai M, Kamide K, Rakugi H, Takiuchi S, Imai M, Kida I, et al. Role of endothelin-1 induced by insulin in the regulation of vascular cell growth. Am J Hypertens 2003; 16:223-228.